TherapeuticsMD Inc (NASDAQ:TXMD) – Investment analysts at Oppenheimer increased their Q3 2018 EPS estimates for shares of TherapeuticsMD in a research report issued to clients and investors on Tuesday, June 5th. Oppenheimer analyst J. Olson now anticipates that the company will post earnings per share of ($0.08) for the quarter, up from their previous estimate of ($0.09). Oppenheimer currently has a “Buy” rating and a $12.00 price target on the stock. Oppenheimer also issued estimates for TherapeuticsMD’s Q4 2018 earnings at ($0.03) EPS, FY2018 earnings at ($0.32) EPS, FY2019 earnings at ($0.10) EPS, FY2020 earnings at $0.22 EPS, FY2021 earnings at $0.44 EPS and FY2022 earnings at $0.70 EPS.
Get TherapeuticsMD alerts:
TherapeuticsMD (NASDAQ:TXMD) last issued its earnings results on Thursday, May 3rd. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.01). The firm had revenue of $3.77 million during the quarter, compared to analysts’ expectations of $4.18 million. TherapeuticsMD had a negative return on equity of 66.77% and a negative net margin of 483.98%. The firm’s quarterly revenue was down 5.4% on a year-over-year basis. During the same period last year, the firm posted ($0.11) earnings per share.
TXMD has been the subject of several other reports. Zacks Investment Research cut shares of TherapeuticsMD from a “hold” rating to a “sell” rating in a report on Wednesday, April 25th. ValuEngine raised shares of TherapeuticsMD from a “strong sell” rating to a “sell” rating in a report on Monday, April 2nd. BidaskClub raised shares of TherapeuticsMD from a “strong sell” rating to a “sell” rating in a report on Saturday, May 26th. Finally, Noble Financial reissued a “buy” rating on shares of TherapeuticsMD in a report on Friday, March 9th. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $15.14.
Shares of TherapeuticsMD stock opened at $7.42 on Friday. TherapeuticsMD has a 52-week low of $4.20 and a 52-week high of $7.66. The stock has a market capitalization of $1.56 billion, a price-to-earnings ratio of -20.05 and a beta of 1.34.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. MANA Advisors LLC purchased a new position in shares of TherapeuticsMD during the fourth quarter valued at approximately $104,000. Paloma Partners Management Co bought a new stake in TherapeuticsMD during the fourth quarter valued at approximately $105,000. Beaumont Financial Partners LLC bought a new stake in TherapeuticsMD during the first quarter valued at approximately $123,000. Xact Kapitalforvaltning AB grew its position in TherapeuticsMD by 96.3% during the first quarter. Xact Kapitalforvaltning AB now owns 31,800 shares of the company’s stock valued at $155,000 after buying an additional 15,600 shares during the period. Finally, Barclays PLC grew its position in TherapeuticsMD by 33,787.3% during the first quarter. Barclays PLC now owns 37,276 shares of the company’s stock valued at $182,000 after buying an additional 37,166 shares during the period. 72.70% of the stock is owned by hedge funds and other institutional investors.
TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.